BRIEF published on 10/30/2025 at 07:35, 7 months 4 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 8 months 3 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 8 months 3 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 8 months 3 days ago rapport financier semestriel 2025
BRIEF published on 08/28/2025 at 20:05, 9 months 5 days ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 9 months 5 days ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 10 months 16 days ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
PRESS RELEASE published on 07/17/2025 at 15:00, 10 months 16 days ago Inside Information / Other news releases GenSight Biologics announces publication on predictors of final visual outcome in patients treated with LUMEVOQ® gene therapy. Study identifies key factors for improved visual acuity post-treatment Gene Therapy GenSight Biologics LUMEVOQ Visual Outcome Predictive Factors
BRIEF published on 07/17/2025 at 08:05, 10 months 17 days ago GenSight Biologics raises 500,000 euros to strengthen its development Funding GenSight Biologics Phase III Gene Therapies LUMEVOQ
BRIEF published on 07/03/2025 at 21:24, 10 months 30 days ago GenSight Biologics completes private placement of nearly €4 million Private Placement Common Shares Euronext Funding GenSight Biologics
Published on 06/03/2026 at 13:25, 14 minutes ago Metallic Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$10 Million
Published on 06/03/2026 at 13:00, 39 minutes ago CoTec Holdings Corp. Joint Venture, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub
Published on 06/03/2026 at 10:30, 3 hours 9 minutes ago Silver Range Partner Excalibur Metals Intersects a Broad Precious Metals Zone, Open at Depth at the Bellehelen Property
Published on 06/03/2026 at 10:00, 3 hours 39 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 13:23, 16 minutes ago CEWE: Annual General Meeting approves 17th consecutive dividend increase
Published on 06/03/2026 at 13:18, 21 minutes ago EQS-Adhoc: Klöckner & Co SE: Decision to launch a delisting tender offer of Worthington Steel at €11.00 per Klöckner & Co-Share published
Published on 06/03/2026 at 13:10, 29 minutes ago SensorUp Closes Growth Financing to Scale its Agentic Operations Platform for Heavy Industry
Published on 06/03/2026 at 12:45, 54 minutes ago Hong Kong forges new opportunities with Kazakhstan and Central Asia
Published on 06/03/2026 at 12:40, 59 minutes ago Infosys and LTA Launch AI-Driven Match and Fan Experiences at the HSBC Championships, and Beyond
Published on 06/03/2026 at 12:41, 58 minutes ago Disclosure of Share Capital and Voting Rights as of Mai 31, 2026
Published on 06/03/2026 at 11:29, 2 hours 10 minutes ago 2026.06.03 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/03/2026 at 08:45, 4 hours 54 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 19 hours 36 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 19 hours 57 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
